LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that several Feraheme® (ferumoxytol) Injection for intravenous (IV) use abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held November 16 - 21, 2010 in Denver, CO, including two AMAG-authored abstracts:
